Arcutis Biotherapeutics v. Padagis: ZORYVE Roflumilast Cream — Voluntarily Dismissed
Arcutis Biotherapeutics filed a six-patent infringement action against Padagis entities in New Jersey over its ZORYVE roflumilast cream 0.3%, a PDE4-inhibitor topical indicated for plaque psoriasis. The complaint was voluntarily dismissed without prejudice just 76 days after filing, before any defendant had answered or moved — leaving the dispute legally unresolved and potentially ripe for refiling.
Six-patent ZORYVE suit ends before Padagis files a single pleading
On March 26, 2024, Arcutis Biotherapeutics, Inc. filed a patent infringement complaint in the U.S. District Court for the District of New Jersey against Padagis Israel Pharmaceuticals Ltd., Padagis LLC, and Padagis US LLC. The suit asserted six U.S. patents — US11129818B2, US10940142B2, US9907788B1, US9884050B1, US11819496B2, and US11793796B2 — in connection with ZORYVE roflumilast cream 0.3%, a topical PDE4 inhibitor approved for plaque psoriasis.
Before any of the three Padagis entities answered, moved, or otherwise responded to the complaint, Arcutis filed a notice of voluntary dismissal on June 10, 2024, invoking Rule 41(a)(1) of the Federal Rules of Civil Procedure. Because no responsive pleading had been filed, the rule permits dismissal as a matter of right. The action was dismissed without prejudice and without costs to either party — meaning no court has evaluated the merits, validity, or scope of any of the six asserted patents.
The 76-day lifespan of the case is notably brief for multi-patent pharmaceutical ANDA-adjacent litigation, where disputes routinely persist for years. The public record is silent on what drove the early exit — possibilities consistent with this pattern include pre-suit settlement negotiations, a licensing arrangement, Padagis withdrawing or amending an ANDA filing, or a strategic decision by Arcutis to re-file in a different venue or with a revised complaint. Because dismissal was without prejudice, Arcutis retains the right to reassert these patents against Padagis.
Filing to Voluntary dismissal in 76 days
76 days — resolved before any defendant response; median ANDA pharma cases run 2–3 years
Voluntarily dismissed: what the Rule 41(a)(1) exit means for both parties
Rule 41(a)(1): dismissal as of right, no court order needed
Under Rule 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order by filing a notice before the defendant serves an answer or a motion for summary judgment. Because no Padagis entity had responded to the complaint, Arcutis held an unconditional right to dismiss. The court played no role in evaluating the merits, and no judgment was entered. The dismissal is self-executing upon filing of the notice.
Procedural exit — no merits rulingWithout prejudice: the public record specifies no-costs, but what does that mean?
The dismissal notice expressly states ‘without prejudice,’ meaning Arcutis retains the right to refile the same claims against the same defendants in the future — subject to any applicable statutes of limitations or consent orders. A dismissal with prejudice would have extinguished those claims permanently. The notice also specifies no costs to either party. The public record does not disclose whether a private settlement or licensing agreement accompanied this exit, so the commercial resolution, if any, remains unknown.
Refiling right preservedArcutis preserves all enforcement options on six roflumilast patents
Because the dismissal is without prejudice, Arcutis retains full ability to reassert US11129818B2, US10940142B2, US9907788B1, US9884050B1, US11819496B2, and US11793796B2 against Padagis or any other ANDA filer. The early exit does not constitute any admission or concession regarding validity or infringement. Arcutis may also have preserved 30-month statutory stays under the Hatch-Waxman framework, depending on the timing of any ANDA certification involved.
All six patents remain enforceablePadagis faces no judgment — but uncertainty persists over ZORYVE generic path
The three Padagis entities emerge from this proceeding without any adverse finding. However, a without-prejudice dismissal does not confer freedom to operate. If Padagis is pursuing an ANDA for a roflumilast cream 0.3% product, the six asserted patents remain live enforcement risks. The absence of a merits ruling means Padagis has not secured a declaratory judgment of invalidity or non-infringement, and any commercial launch would carry continued litigation exposure.
No FTO certainty achievedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ARCUTIS BIOTHERAPEUTICS, INC. | Company | Specialty dermatology biopharma — holder of US11129818B2 and 5 further roflumilast patentsSearch in Eureka ↗ |
| Defendant | Padagis Israel Pharmaceuticals, Ltd. | Company | Generic pharmaceutical manufacturer with U.S. and Israeli entities; target of ZORYVE cream IP suitSearch in Eureka ↗ |
| Co-Defendant | Padagis, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Padagis US, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Christine Clark | Attorney | Counsel for ARCUTIS BIOTHERAPEUTICS, INC.Search in Eureka ↗ |
| Plaintiff counsel | Joseph L. Linares | Attorney | Counsel for ARCUTIS BIOTHERAPEUTICS, INC.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for ARCUTIS BIOTHERAPEUTICS, INC.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing ARCUTIS BIOTHERAPEUTICS, INC.Search in Eureka ↗ |
| Defendant counsel | Melissa Ellen Flax | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant law firm | Carella Byrne Cecchi Olstein Brody & Agnello, PC | Law Firm | Representing Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) precisely — Arcutis confirms that no defendant had answered or moved, establishing the procedural predicate for dismissal as of right. The explicit ‘without prejudice’ and ‘without costs’ language is significant: it forecloses any argument that the dismissal constitutes a merits concession or a settlement with prejudicial effect. The six-patent scope of the original complaint suggests this was not a routine housekeeping filing, and the pre-answer timing is consistent with confidential negotiations resolving the immediate dispute while leaving long-term enforcement leverage intact.
US11129818B2 and five further patents — roflumilast topical cream formulations
The six asserted patents — US11129818B2, US10940142B2, US9907788B1, US9884050B1, US11819496B2, and US11793796B2 — cover formulation, composition, and method-of-use aspects of roflumilast cream 0.3%, marketed as ZORYVE. Roflumilast is a selective PDE4 inhibitor; its topical application for inflammatory skin conditions such as plaque psoriasis represents a distinct formulation challenge relative to its oral form. The application dates span from 2017 (US15/676356) through 2023 (US18/176601), suggesting Arcutis has pursued a rolling prosecution strategy to build layered IP coverage as the product reached and remained on market.
The breadth of the asserted portfolio — six patents across multiple application families — is commercially significant. It indicates Arcutis is not relying on a single formulation claim but has constructed overlapping protection covering the cream vehicle, active concentration, and therapeutic methods. For generic manufacturers, this multi-layered structure substantially increases the design-around burden and litigation exposure. Any competitor seeking to develop a roflumilast cream or closely analogous PDE4-inhibitor topical product should treat this patent family as a core FTO priority, particularly given that the newest patent (US11819496B2) issued as recently as 2023.
Should your team run an FTO against Arcutis’s roflumilast cream patent family?
Any pharmaceutical or specialty dermatology company developing a topical roflumilast cream, a generic equivalent to ZORYVE, or a PDE4-inhibitor topical product in a comparable cream vehicle should treat the six Arcutis patents as mandatory FTO targets. The combination of patents spanning formulation composition, concentration-specific claims, and method-of-use creates substantial infringement risk even for products designed to differ from ZORYVE in secondary characteristics. With the newest patent dating to 2023, the exclusivity horizon extends well into the 2040s for certain family members.
PatSnap Eureka’s FTO Search Agent can map your candidate formulation against each of the six asserted patents simultaneously, flagging claims that may read on your product and identifying prior art that could support invalidity arguments. Eureka also tracks the full Arcutis prosecution history across all six applications, enabling your team to monitor continuation filings that may extend coverage further. For ANDA filers, Eureka’s litigation monitoring feature flags new suits involving these patents in real time — critical for assessing 30-month stay exposure and refile risk.
Run a freedom-to-operate analysis on US11129818B2 to assess your product’s exposure
Run FTO in Eureka →Similar roflumilast and topical dermatology patent cases in U.S. district courts
Explore related Hatch-Waxman infringement actions involving roflumilast, topical PDE4 inhibitors, and specialty dermatology formulation patents filed in New Jersey and peer district courts.
What this case signals for the topical dermatology IP landscape
A six-patent suit that ends in 76 days without a single defendant pleading raises pointed questions about ANDA strategy and roflumilast exclusivity.
Early voluntary dismissals in ANDA cases often signal off-docket resolution
When a brand-name plaintiff drops a Hatch-Waxman suit before defendants respond, it consistently suggests a private negotiation has occurred — whether a consent judgment, licensing agreement, or ANDA amendment. IP teams monitoring ZORYVE’s generic competitive horizon should track whether Padagis re-enters the market with a modified product or an agreed entry date.
Six-patent portfolio signals deep formulation exclusivity around roflumilast cream
Arcutis asserted six distinct patents across two application families, suggesting layered protection covering formulation composition, methods of use, and potentially manufacturing processes. Competitors developing roflumilast or other PDE4-inhibitor topical products should conduct thorough FTO analysis across the full Arcutis portfolio before advancing into late-stage development.
ARCUTIS v Padagis — key questions answered
The public record does not disclose Arcutis’s reason for dismissal. Under Rule 41(a)(1), a plaintiff may dismiss as of right before any defendant answers. Patterns consistent with this outcome include confidential settlement, licensing discussions, an ANDA amendment by Padagis, or a strategic decision to refile. The without-prejudice designation means Arcutis retains full right to reassert the six patents.
Arcutis asserted six U.S. patents: US11129818B2, US10940142B2, US9907788B1, US9884050B1, US11819496B2, and US11793796B2. All relate to ZORYVE roflumilast cream 0.3%, a topical PDE4 inhibitor for plaque psoriasis. The patents span formulation compositions and methods of use across multiple prosecution families filed between 2017 and 2023.
No. A voluntary dismissal without prejudice does not constitute a finding of non-infringement or invalidity. The six Arcutis patents remain in force and enforceable. Padagis did not obtain a declaratory judgment of invalidity or non-infringement, so any commercial launch of a roflumilast cream 0.3% product would still carry infringement exposure under the existing patent portfolio.
Rule 41(a)(1) allows a plaintiff to dismiss an action without court approval before the defendant serves an answer or summary judgment motion. In a Hatch-Waxman context, this exits the litigation but does not necessarily terminate any 30-month stay triggered by a Paragraph IV ANDA certification. The brand-name plaintiff also preserves the right to file a new infringement action, restarting litigation if the generic ANDA filing proceeds.
Yes. Because the dismissal was expressly without prejudice, Arcutis retains the right to refile an infringement action based on the same or additional patents against the Padagis entities. A second voluntary dismissal on the same claims might, under Rule 41(a)(1)(B), operate as a dismissal with prejudice — the so-called ‘two-dismissal rule’ — so any refile decision would require careful procedural consideration.
PatSnap Eureka searches patents and litigation data to answer instantly.